Bolt Biotherapeutics Inc (FRA:6LP)
€ 0.692 -0.006 (-0.86%) Market Cap: 26.39 Mil Enterprise Value: -39.58 Mil PE Ratio: 0 PB Ratio: 0.28 GF Score: 43/100

Bolt Biotherapeutics Inc at Cowen Health Care Conference Transcript

Mar 07, 2023 / 07:50PM GMT
Release Date Price: €1.53 (-2.55%)
Boris Peaker
TD Cowen - Analyst

Fantastic. Thanks, everybody, for joining. The next company to present is Bolt Biotherapeutics. And it's my pleasure to introduce Randall Schatzman, the CEO of Bolt. Thanks, Randall.

Randall Schatzman
Bolt Biotherapeutics - CEO

Thank you, Boris. Thanks for the kind introduction. It's a pleasure to be here today. And thanks to the team at TD Cowen for inviting us to participate in the conference. We've had a great schedule so far.

So I wanted to acknowledge a couple of my colleagues who are joining me today. Willie Quinn, who's Bolt's Chief Financial Officer; and Edith Perez, who's Bolt's Chief Medical Officer. And all of us will be available to answer your questions after my opening remarks here. So we will be making some forward-looking statements today, and I encourage listeners to refer to our filings with the SEC to understand the risks of our business along the way.

And Bolt, we're pursuing a strategy of novel immuno-oncology therapeutics that are targeted and allow us to access both the innate and the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot